The pharmaceuticals landscape is changing, in a positive way, and there is a growing appetite from both business and regulators for new technology and processes that can bring cost and sustainability savings. 

We've spent the summer working on

• commercially competitive Bio2Amine processes,

• showcasing our tech running routinley in higher TRL reactors, and

• demonstrating a 18-fold improvement in enzyme manufacturing increasing our cost-competitivity across the chemicals sector!

HydRegen’s Bio2Amine technology delivers sustainable, cost-efficient and safe chemical manufacturing with the power of biology: underpinning science published in Nature Communications.

HydRegen successfully completes tech transfer to Almac Sciences as part of the joint development project of its proprietary enzyme platform.